Starpharma and Elanco Sign Agreement
MELBOURNE, May 11 /Medianet International-AsiaNet/ --
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced the signing
of a collaborative research, license and commercialisation agreement with Elanco,
the animal health division of US pharmaceutical company Eli Lilly and Company.
The parties will collaborate to develop new animal health products with
enhanced properties using Starpharma’s dendrimer technology. Under the agreement,
Starpharma will receive revenue from research fees, and is eligible for milestone
payments and royalties on sale of any product developed. Elanco will receive
exclusivity within the animal health field. Terms were not disclosed.
"We are very pleased to have secured such a strong animal health partner as
Elanco for our delivery technology," said Dr Jackie Fairley, CEO, Starpharma.
"Their expertise, resources and market presence will be enormously valuable
assets as we work to bring these innovative products to market," Fairley said.
"An exciting aspect of this application for our business is that product
development in the animal health sector can be faster than is usually associated
with the development of human drugs."
The collaboration with Elanco is further demonstration of Starpharma’s strong
and successful partnership model and the multiple potential applications of its
dendrimer technology. Starpharma also has partnerships with SSL International
(Durex®), Siemens (Dade Behring), EMD Merck, Stiefel, Unilever, Qiagen and Sigma
Aldrich.
Starpharma retains all rights to exploit the technology outside of Elanco’s
specific field of interest, including for all uses in humans, and continues to
work to add to its portfolio of partners for drug delivery and dendrimer
technology more widely.
In 2008, the global animal health market was reported to be about US$19
billion. Global sales are expected to reach US$21.7B by 2010, at which time the
top three markets are forecast to be USA, China and Brazil, with the USA
accounting for 40 percent of growth [1] .
About Starpharma
Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a world leader in the
development of dendrimer nanotechnology for pharmaceutical, life-science and
other applications. SPL has two operating companies, Starpharma Pty Ltd in
Melbourne, Australia and DNT, Inc in the USA. Products based on SPL’s dendrimer
technology are already on the market in the form of diagnostic elements and
laboratory reagents through licence arrangements with partners including Siemens
and Merck KgA.
For further information:
MediaBuchan Consulting
Rebecca Wilson
Tel: +61 3 9866 4722
Mob: +61 417 382 391
rwilson@bcg.com.au
Ellie Papathanasiou
Tel: +61 2 9237 2800
epapathanasiou@bcg.com.au
Starpharma
Dr Jackie Fairley Chief Executive Officer
+61 3 8532 2704
Ben Rogers Company Secretary
+61 3 8532 2702
ben.rogers@starpharma.com
[1]Vetnosis for global animal health market estimate; all other information in
"World Animal Health Markets" from Informa Healthcare, January 2008.
SOURCE: Starpharma
NEWS 
